Regulation of T cell homeostasis by IFN-gamma
IFN-γ 对 T 细胞稳态的调节
基本信息
- 批准号:7747962
- 负责人:
- 金额:$ 35.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-07-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAmpicillinAntigensApoptosisBiological ModelsBiologyCD8B1 geneCellsCharacteristicsCommunicable DiseasesContractsDataExhibitsFundingGene TargetingGenerationsGenesGoalsGrantHomeostasisInfectionInterferon Gamma Receptor ComplexInterferon Type IIInterferon-alphaInterleukin-18Listeria monocytogenesMediatingMemoryMessenger RNAMicroarray AnalysisModelingMolecularMusPathway interactionsPhasePlayProductionProtein p53ProteinsReceptor SignalingRoleSignal TransductionSignaling MoleculeSourceT cell regulationT cell responseT-LymphocyteTP53 geneTimeTumor Suppressor GenesVaccinationVirus Diseasesbasecellular targetingcostcytokineinterleukin-18 receptornovelpathogenreceptortranscription factor
项目摘要
During the initial funding period for this proposal, we made substantial progress in developing novel
model systems to identify the specific aspects of T cell homeostasis that are influenced by IFN-gamma.
Strikingly, these studies reveal that IFN-gamma produced after infection is able to regulate the initial
expansion of antigen-specific CD8 T cells, the contraction phase and the rate at which T cells acquire
memory characteristics. These data underlie and support our overall hypothesis for the current proposal, that
that IFN-gamma is a major regulator of T cell homeostasis after infection. In this proposal, we will employ
the model systems we developed in the preceding funding period to address the cellular and molecular basis
for IFN-gamma regulation of T cell contraction. In addition, we will extend our studies to address the cross-
talk between IFN-alpha-beta receptor and IFN-gamma receptor signaling in regulating the expansion of CDS
T cells after infection. Our long-term goal is to understand how IFN-gamma and other signaling molecules
regulate specific aspects of T cell homeostasis, such that this information can be used to enhance the T cell
response to vaccination. Improvements in vaccination will allow the most cost effectiveand widespread
defense against infectious disease. We will address our long-term goal through the following specific aims:
Specific Aim 1. Determine the timing, source, quantity and cellular targets of IFN-gamma required to
regulate CDST cell contraction.
Specific Aim 2. Determine if IFN-gamma regulates T cell contraction through p53 and/or IL-18 signaling.
Specific Aim 3. Determine the requirements for IFN-alpha-beta and IFN-gamma signaling in regulating CDS
T cell expansion.
在这项建议的最初资助期间,我们在开发新的
模型系统,以确定受IFN-γ影响的T细胞稳态的具体方面。
引人注目的是,这些研究表明,感染后产生的IFN-γ能够调节最初的
抗原特异性CD 8 T细胞的扩增、收缩期和T细胞获得免疫应答的速率
记忆特性这些数据支持我们对当前提案的总体假设,即
IFN-γ是感染后T细胞稳态的主要调节因子。在本提案中,我们将采用
我们在前一个资助期开发的模型系统,以解决细胞和分子基础
用于IFN-γ调节T细胞收缩。此外,我们将扩大我们的研究,以解决交叉-
IFN-α-β受体和IFN-γ受体信号在调节CDS扩增中的作用
感染后的T细胞我们的长期目标是了解IFN-γ和其他信号分子如何
调节T细胞稳态的特定方面,使得该信息可用于增强T细胞免疫应答。
接种疫苗的反应。疫苗接种的改进将使最具成本效益和最广泛的
防御传染病。我们将通过以下具体目标实现我们的长期目标:
具体目标1.确定IFN-γ的时间、来源、数量和细胞靶点,
调节CDST细胞收缩。
具体目标2。确定IFN-γ是否通过p53和/或IL-18信号调节T细胞收缩。
具体目标3。确定在调节CDS中IFN-α-β和IFN-γ信号传导的要求
T细胞扩增。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John T Harty其他文献
John T Harty的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John T Harty', 18)}}的其他基金
Regulating Pathogen-induced Protective and Pathogenic CD8 T cells in the CNS
调节中枢神经系统中病原体诱导的保护性和致病性 CD8 T 细胞
- 批准号:
10722304 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Memory CD8 T cell immunity to respiratory viral infections
记忆 CD8 T 细胞对呼吸道病毒感染的免疫
- 批准号:
8699313 - 财政年份:2013
- 资助金额:
$ 35.81万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8369810 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8830912 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8639463 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
Understanding immune regulation in blood-stage malaria
了解血期疟疾的免疫调节
- 批准号:
10192639 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
8462904 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
T cell Inhibitory receptor blockade in chronic blood-stage malaria
慢性血期疟疾中的 T 细胞抑制性受体阻断
- 批准号:
9054060 - 财政年份:2012
- 资助金额:
$ 35.81万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 35.81万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 35.81万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 35.81万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 35.81万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 35.81万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 35.81万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 35.81万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 35.81万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 35.81万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 35.81万 - 项目类别: